OWC Pharmaceutical Research (OWC Pharmaceutical Research) Total Liabilities : $5.78 Mil (As of Sep. 2019)

View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research Total Liabilities?

OWC Pharmaceutical Research's Total Liabilities for the quarter that ended in Sep. 2019 was $5.78 Mil.

OWC Pharmaceutical Research's quarterly Total Liabilities declined from Mar. 2019 ($13.19 Mil) to Jun. 2019 ($5.38 Mil) but then increased from Jun. 2019 ($5.38 Mil) to Sep. 2019 ($5.78 Mil).

OWC Pharmaceutical Research's annual Total Liabilities declined from Dec. 2016 ($0.40 Mil) to Dec. 2017 ($0.27 Mil) but then increased from Dec. 2017 ($0.27 Mil) to Dec. 2018 ($12.99 Mil).

OWC Pharmaceutical Research Total Liabilities Historical Data

The historical data trend for OWC Pharmaceutical Research's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research Total Liabilities Chart

OWC Pharmaceutical Research Annual Data

Trend

Dec08

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Total Liabilities

Get a 7-Day Free Trial

0.06

0.11

0.40

0.27

12.99

OWC Pharmaceutical Research Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Total Liabilities	Get a 7-Day Free Trial															8.10	12.99	13.19	5.38	5.78

OWC Pharmaceutical Research Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

OWC Pharmaceutical Research's Total Liabilities for the fiscal year that ended in Dec. 2018 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.438	+	(0	+	12.555
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	12.99

Total Liabilities	=	Total Assets (A: Dec. 2018 )	-	Total Equity (A: Dec. 2018 )
	=	3.553	-	-9.44
	=	12.99

OWC Pharmaceutical Research's Total Liabilities for the quarter that ended in Sep. 2019 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.543	+	(0.021	+	5.217
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	5.78

Total Liabilities	=	Total Assets (Q: Sep. 2019 )	-	Total Equity (Q: Sep. 2019 )
	=	1.773	-	-4.008
	=	5.78

OWC Pharmaceutical Research Total Liabilities Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ben Gurion Street, Ramat Gan, ISR, 5257334

Website

http://www.owcpharma.com

OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.

Executives

Asher Zwebner

director, officer: CHIEF FINANCIAL OFFICER

CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387